.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers are currently investigating advanced strategies for cancer metastasis suppression by targeting the intricate link between cellular metabolism and movement. Despite significant progress in oncology, metastatic disease remains the leading cause of cancer-related mortality worldwide. A recent review highlights a bidirectional network where mitochondrial metabolism and Rho GTPase signaling reinforce each other. Consequently, this synergy allows cancer cells to adapt their energy production and mechanical structure during the invasion process.
Mitochondria serve as the primary power source, providing the ATP and reactive oxygen species (ROS) necessary to fuel Rho GTPase signaling. Furthermore, these Rho GTPases orchestrate the cytoskeletal dynamics required for cell migration and invasion. Interestingly, the relationship is reciprocal. As the cell reshapes its cytoskeleton, it signals for the redistribution of mitochondria to areas with high energy demand. Therefore, this feedforward loop significantly accelerates the metastatic spread of neoplastic cells.
The review proposes a dual-targeting framework to break this cycle of resistance. By combining Rho GTPase silencing via small interfering RNA (siRNA) with mitochondrial inhibition through repurposed antibiotics, clinicians might disrupt both the metabolic fuel and the structural engine of the cell. This combination therapy aims to overcome the adaptive resistance that often renders single-target treatments ineffective. Moreover, this translational framework provides a clear path for developing next-generation anti-metastatic interventions.
Mitochondria provide essential ATP and reactive oxygen species that activate Rho GTPase signaling. This process fuels the mechanical movement and structural changes necessary for cancer cells to invade distant tissues.
Single-target therapies often fail because cancer cells adapt by using alternative pathways. By targeting both the metabolic energy source and the mechanical signaling system simultaneously, the dual strategy minimizes the chance of compensatory resistance.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Daher A et al. Dual targeting of mitochondrial metabolism and Rho GTPase signaling to suppress cancer metastasis (Review). Oncol Rep. 2026 Aug undefined. doi: undefined. PMID: 42246188.
Spinrad MW et al. Dual targeting of oncogenic microtubules and mitochondria in PDAC. Oncoscience. 2026 Jan 28;13. doi: 10.18632/oncoscience.593.
Metabolic adaptations in cancer progression. Physiological Reviews. 2024. doi: 10.1152/physrev.00010.2023.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new review proposes a dual-targeting strategy using mitochondrial inhibition and Rho GTPase silencing to disrupt the metabolic drivers of cancer metastasi...
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
